Boehringer Ingelheim: all 2,305 studies
Page 17 of 24. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes MellitusCompletedNCT02242825
- Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate HypertensionTerminatedNCT02242812Phase 4
- A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)CompletedNCT02242396
- Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With HypertensionCompletedNCT02242383
- Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential HypertensionCompletedNCT02242370Phase 4
- Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionCompletedNCT02242357
- Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With HypertensionCompletedNCT02242344Phase 2
- Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood PressureCompletedNCT02242331
- Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure MonitoringCompletedNCT02242318Phase 4
- Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and DiscomfortCompletedNCT02242292Phase 2
- Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD PatientsCompletedNCT02242279Phase 2
- Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242266Phase 2
- Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242253Phase 2
- Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242240Phase 2
- Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02242227Phase 2
- Effect of Caldine® on Renal Function in Balanced HypertensionTerminatedNCT02240641
- Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 PatientsTerminatedNCT02239835Phase 2
- Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV PatientsCompletedNCT02238314Phase 2
- Post-Marketing Surveillance Study of Micardis® Plus in Patients With HypertensionCompletedNCT02238275
- Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsCompletedNCT02238262
- Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With UrticariaCompletedNCT02238249
- Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and PruritusCompletedNCT02238236
- Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® TabletCompletedNCT02238223
- Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or AllergyCompletedNCT02238210Phase 4
- Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238197
- Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238184
- Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238171
- Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseaseCompletedNCT02238158
- Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways DiseaseCompletedNCT02238145
- Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways DiseaseCompletedNCT02238132
- Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238119Phase 2
- Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02238106Phase 2
- The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and PneumoniaCompletedNCT02236741
- Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With PramipexoleCompletedNCT02236728
- Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways DiseaseCompletedNCT02236715
- Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236182Phase 2
- Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236169Phase 2
- Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young ChildrenTerminatedNCT02235428Phase 4
- Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential HypertensionCompletedNCT02235415
- A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive PatientsCompletedNCT02235402Phase 4
- A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)TerminatedNCT02235389
- Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive BronchitisCompletedNCT02233920
- Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233907
- Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233894
- Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseaseCompletedNCT02233881
- Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseCompletedNCT02233023Phase 4
- Efficacy and Safety of Lacidipine in Chronic Stable AnginaCompletedNCT02232607Phase 2
- Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02232594
- Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic FailureCompletedNCT02232581Phase 2
- Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and PainCompletedNCT02232555Phase 3
- Tolerability and Safety of Duloxetine BID in Healthy Female SubjectsCompletedNCT02232542Phase 1
- Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and RosuvastatinCompletedNCT02231931Phase 1
- Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's DiseaseCompletedNCT02231905Phase 4
- Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract DiseaseCompletedNCT02231437
- Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways DiseaseCompletedNCT02231424
- Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways DiseaseCompletedNCT02231372
- Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways DiseaseCompletedNCT02231359
- Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02231346
- Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02231320
- The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02231294
- Observational Study to Assess a 6-months Treatment With GlademCompletedNCT02231268
- Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02231255
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisNo longer availableNCT02230982
- An International Observational Study of the Safety and Efficacy of Thrombolysis in StrokeCompletedNCT02229890
- Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of FoodCompletedNCT02229838Phase 1
- Safe Implementation of Thrombolysis in Stroke - Monitoring StudyCompletedNCT02229812
- Protocol for Post Marketing Surveillance of Actilyse VialTerminatedNCT02229799
- Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal SpasmsCompletedNCT02229786Phase 2
- Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male SubjectsCompletedNCT02229773Phase 1
- Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIVTerminatedNCT02229760Phase 1/2
- Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or LaryngitisCompletedNCT02229747Phase 4
- Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy SubjectsCompletedNCT02227030Phase 1
- Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy VolunteersCompletedNCT02227017Phase 1
- Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult VolunteersCompletedNCT02226991Phase 1
- Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy VolunteersCompletedNCT02226978Phase 1
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT02226952Phase 1/2
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis CCompletedNCT02226939Phase 2
- Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy VolunteersCompletedNCT02226926Phase 1
- Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male SubjectsCompletedNCT02225626Phase 1
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male SubjectsCompletedNCT02224105Phase 1
- Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male VolunteersCompletedNCT02224079Phase 1
- Lendormin D® Tablet (Drug Use Result Survey)CompletedNCT02224014
- Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female VolunteersCompletedNCT02223507Phase 1
- Safety of Terbogrel in Patients With Primary Pulmonary HypertensionTerminatedNCT02223494Phase 2
- Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary HypertensionCompletedNCT02223481Phase 2
- Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female SubjectsCompletedNCT02223026Phase 1
- Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy SubjectsCompletedNCT02223013Phase 1
- Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy SubjectsCompletedNCT02223000Phase 1
- Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male SubjectsCompletedNCT02222987Phase 1
- Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CLCompletedNCT02222974Phase 1
- Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male VolunteersCompletedNCT02222961Phase 1
- Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersCompletedNCT02222428Phase 1
- Relative Bioavailability of BI 671800 HEA in Healthy Male VolunteersCompletedNCT02222233Phase 1
- Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersCompletedNCT02221414Phase 1
- Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersCompletedNCT02221401Phase 1
- Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female VolunteersCompletedNCT02221388Phase 1
- Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male VolunteersCompletedNCT02221375Phase 1
- Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)CompletedNCT02220673Phase 1
- Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersCompletedNCT02220660Phase 1
- Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersCompletedNCT02220647Phase 1